The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapy with metronomic cyclophosphamide (mCyc) in metastatic castrate resistant prostate cancer (mCRPC) and genomic correlates.
 
Nataliya Mar
Speakers' Bureau - Astellas Pharma; Aveo; Eisai; Seagen; Tempus
 
Sami Dwabe
No Relationships to Disclose
 
Kevin Kayvan Zarrabi
Consulting or Advisory Role - Eisai
 
Aditya Eturi
No Relationships to Disclose
 
William Kevin Kelly
Honoraria - Janssen Oncology
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Genentech; Gilead Sciences; Immunomedics; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Exelixis; Genentech/Roche; Gilead Sciences; Gilead Sciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus